The Promise and Challenges of Rare Cancer Treatments

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Dr. William Smith, Pioneer Institute’s Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, and concerns about cost effectiveness tools such as the Quality Adjusted Life Year (QALY), in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th Can Forum.

Watch the video below:

Get Updates On Our Life Sciences Work!

Related Content:

The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews

/
This op-ed by William Smith appeared in STAT News on February…

Baker’s Orwellian drug pricing policy

/
This op-ed by William Smith appeared in Commonwealth Magazine…

Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments

Review methodology could negatively impact elderly, the disabled,…